Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306
XENCOR (NASDAQ: XNCR) Delayed: 24.59 +0.88 (3.71%)
Previous Close $23.71    52 Week High $26.50 
Open $24.25    52 Week Low $9.89 
Day High $24.87    P/E N/A 
Day Low $23.98    EPS $-0.51 
Volume 1,027,007